Huang Michael F. Insider Trading Activity (SLNO)

Summary

Updated Jul 16, 2026

Huang Michael F. has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $200K.

Profile

Michael F. Huang is the Senior Vice President of Clinical Development at Soleno Therapeutics Inc. as of the SEC filing dated January 23, 2026 (CIK 0002019992). In this role, he oversees clinical development strategy for Soleno's DCCR (Diazoxide Choline) program. The filing reports no securities purchases or sales by him in that period.

Role	Insider
Notability	35/100

Board memberships

Soleno Therapeutics Inc.

Awards & honors

Led clinical development strategy for Soleno's DCCR program.
Coordinated cross-functional teams across translational science, clinical trials, and regulatory planning.
Oversaw interactions with regulatory authorities for rare-disease therapies.

Recent Transactions

Date	Ticker	Company	Code	Shares	Price	Value
2026-05-18	SLNO	SOLENO THERAPEUTICS INC	D — Derivative transaction	39.8K	—
2026-04-01	SLNO	SOLENO THERAPEUTICS INC	S — Open-market sale	488	$31.72	$15K
2026-04-01	SLNO	SOLENO THERAPEUTICS INC	S — Open-market sale	1.8K	$31.04	$57K
2026-04-01	SLNO	SOLENO THERAPEUTICS INC	S — Open-market sale	4.3K	$30.04	$128K
2026-01-23	SLNO	SOLENO THERAPEUTICS INC	A — Grant or award	10.4K	$0.00

Frequently Asked Questions

Who is Huang Michael F.?

How many SEC Form 4 filings has Huang Michael F. submitted recently?

1 primary Form 4 filings in the last 90 days, covering 1 company.

Has Huang Michael F. been buying or selling stock?

Recorded transactions: 0 open-market purchases () and 3 open-market sales ($200K) across all tracked filings.

Where can I see all of Huang Michael F.'s SEC filings?

All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.

Huang Michael F. — SEC Form 4 Insider Trading Activity